Trial
NCT02937168
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
—
Condition
Asthma
Intervention
Reslizumab
Why stopped
The study was terminated early due to challenges in recruitment. The decision to terminate the study was not related to any safety issues or concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-09